MedTrace Logo

Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 Months

NCT07507500 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 8100

Last updated 2026-04-02

No results posted yet for this study

Summary

This study is testing different blood-thinning treatment strategies for people who have had a heart attack and were successfully treated with a coronary stent procedure (PCI). All strategies tested are already approved for this condition and used inversally. This study will define which of the approved strategies is the best one.

After PCI, patients usually receive two antiplatelet medicines for up to 12 months to help prevent another heart attack or stroke, but this treatment can also increase bleeding risk. This study will compare a shorter course of dual antiplatelet therapy followed by one antiplatelet medicine alone versus the standard 12-month course. In addition, the study will compare two commonly used antiplatelet drugs, prasugrel and ticagrelor. The goal is to find out which strategy best prevents death, heart attack, or stroke while minimizing serious bleeding.

This study is not testing any new intervention, rather comparing approved drugs and approved durations of use.

Conditions

  • Myocardial Infarction (MI)

Interventions

DRUG

Prasugrel

Prasugrel during 12 months

DRUG

Ticagrelor

Ticagrelor plus aspirin

Sponsors & Collaborators

  • Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III

    collaborator OTHER

  • Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

    lead OTHER

Principal Investigators

  • Borja Ibanez, MD PhD · Centro Nacional de Investigaciones Cardiovasculares (CNIC) & Fundacion Jimenez Díaz University Hospital (IIS-FJD)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2029-07-31
Completion
2030-01-31

Countries

  • Ireland
  • Latvia
  • Norway
  • Poland
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07507500 on ClinicalTrials.gov